Descripción
Boldenone by Genpharma is a high-purity depot injectable formulation widely valued for its ability to deliver solid, quality muscle tissue growth without excessive water retention.
Thanks to its undecylenate ester, this compound ensures extended-release activity, optimizing the cellular anabolic environment, stimulating red blood cell production, and significantly improving endurance and vascularity.
- General Information
- Brand Name: Boldenone Genpharma.
- Active Ingredient: Boldenone Undecylenate.
- Concentration: 250 mg/ml.
- Presentation: 10 ml Multidose Vial / Injectable Ampoules.
- Route of Administration: Deep Intramuscular (I.M.) injection.
- Composition
Each ml contains:
- Boldenone Undecylenate: 250 mg.
- Excipients: Pharmaceutical-grade carrier oil, benzyl alcohol, and benzyl benzoate.
- Pharmacological Properties & Benefits
- Steady Lean Muscle Gains: Promotes consistent muscle hypertrophy with minimal subcutaneous fluid retention.
- Appetite & Protein Synthesis: Enhances nutrient partitioning and nitrogen retention for optimal recovery.
- Enhanced Erythropoiesis: Increases red blood cell count, improving oxygen delivery, stamina, and muscular vascularity.
- Low Aromatization Rate: Converts to estrogen at a significantly lower rate than standard testosterone.
- Reconstitution & Storage
- Reconstitution: Ready-to-inject oil solution; requires no reconstitution.
- Storage Temperature: Store at controlled room temperature between 15°C and 25°C (59°F to 77°F).
- Protection: Keep protected from direct sunlight and humidity. Do not freeze.
- Warnings & Safety
- Professional Use: Intended for professional or qualified supervisor guidance.
- Contraindications: Contraindicated in individuals with hormone-dependent carcinomas or hypersensitivity to boldenone.
- Medical Monitoring: Regular monitoring of hematocrit levels and lipid profiles is recommended.
- Side Effects: Potential mild androgenic effects (acne, oily skin) and endogenous HPTA suppression.
- Child Safety: Keep out of reach of children.




